Contemporary treatment and outcome of sinonasal undifferentiated carcinoma: A meta-analysis

IF 4.6 Q2 MATERIALS SCIENCE, BIOMATERIALS ACS Applied Bio Materials Pub Date : 2024-08-20 DOI:10.1002/hed.27910

Manuela Burggraf MD, Stefan Schiele PhD, Rubens Thölken MD, Francisco José Farfán López MD, Noran Elawany, Johannes Zenk PhD, Johannes Doescher PhD

{"title":"Contemporary treatment and outcome of sinonasal undifferentiated carcinoma: A meta-analysis","authors":"Manuela Burggraf MD, Stefan Schiele PhD, Rubens Thölken MD, Francisco José Farfán López MD, Noran Elawany, Johannes Zenk PhD, Johannes Doescher PhD","doi":"10.1002/hed.27910","DOIUrl":null,"url":null,"abstract":"Induction chemotherapy (IC) recently gained importance for treatment of sinonasal undifferentiated carcinoma (SNUC). We analyzed our SNUC cases and performed a meta-analysis with focus on survival-rates stratified by treatment. SNUC cases at our institution were retrospectively evaluated. A systematic literature review was conducted to analyze treatment and outcome of SNUC. To calculate 5-year and 2-year overall survival (OS), individual patient data (IPD) were analyzed using Kaplan–Meier estimators and Cox proportional hazard regression to identify associations between types of therapy and survival. A random effects model for pooled estimates of 5-year survival was applied to studies without IPD data. Five-year OS of our SNUC cases (n = 9) was 44.4%. The IPD analysis (n = 192) showed a significantly better 5-year OS for patients who received induction chemotherapy (72.6% vs. 44.5%). The pooled 5-year OS of 13 studies identified in the literature search was 43.8%. IC should be considered in every patient diagnosed with SNUC.","PeriodicalId":2,"journal":{"name":"ACS Applied Bio Materials","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2024-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hed.27910","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Bio Materials","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/hed.27910","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}

引用次数: 0

Abstract

Induction chemotherapy (IC) recently gained importance for treatment of sinonasal undifferentiated carcinoma (SNUC). We analyzed our SNUC cases and performed a meta-analysis with focus on survival-rates stratified by treatment. SNUC cases at our institution were retrospectively evaluated. A systematic literature review was conducted to analyze treatment and outcome of SNUC. To calculate 5-year and 2-year overall survival (OS), individual patient data (IPD) were analyzed using Kaplan–Meier estimators and Cox proportional hazard regression to identify associations between types of therapy and survival. A random effects model for pooled estimates of 5-year survival was applied to studies without IPD data. Five-year OS of our SNUC cases (n = 9) was 44.4%. The IPD analysis (n = 192) showed a significantly better 5-year OS for patients who received induction chemotherapy (72.6% vs. 44.5%). The pooled 5-year OS of 13 studies identified in the literature search was 43.8%. IC should be considered in every patient diagnosed with SNUC.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

鼻窦未分化癌的现代治疗方法和疗效：一项荟萃分析。

最近，诱导化疗（IC）在鼻窦鼻腔未分化癌（SNUC）的治疗中变得越来越重要。我们分析了本院的鼻窦未分化癌病例，并进行了一项荟萃分析，重点关注按治疗方法分层的生存率。我们对本机构的鼻窦未分化癌病例进行了回顾性评估。我们进行了系统的文献回顾，分析了SNUC的治疗和结果。为了计算5年和2年总生存率（OS），我们使用卡普兰-梅耶估计器和Cox比例危险回归分析了单个患者数据（IPD），以确定治疗类型与生存率之间的关联。对于没有IPD数据的研究，则采用随机效应模型对5年生存率进行汇总估计。我们的SNUC病例（n = 9）的5年OS为44.4%。IPD分析（n = 192）显示，接受诱导化疗的患者的5年生存率明显更高（72.6%对44.5%）。文献检索中发现的13项研究的5年生存率合计为43.8%。每一位确诊为SNUC的患者都应考虑接受IC治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊